Agilent Technologies (A)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
$181.15-0.18%
Close 2026-10-29 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
Research Workspace
Put A beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
Agilent's China, replacement-cycle, and lab-automation growth must sustain revenue growth. Revenue growth slowed from 10.0% in Q2 to 8.1% in Q3. Q3 earnings beat estimates by 9.5%, and quarterly revenue reached $1.88 billion. Agilent trades at 30× earnings versus the 37× peer median. Its 24.5× historical multiple is below today's multiple. The price reflects less growth than our forecast. A 17.0% modeled next-quarter miss risk could challenge the growth case. The premium over peers could shrink if growth does not support it. Peer multiples imply a price about 9% below where it trades. Our read remains intact.
Trailing returns as of 2026-10-29. A is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 23 analysts currently covering A (as of Oct 2026).
Based on 11 Wall Street analysts offering 12-month price targets for A in the last 4 months.
Continue this research
Compare A with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| A Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put A next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive revenue growth for fiscal year 2026
Growth from China supports revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $181.15
The last 12 months of price, then the range of analyst 12-month targets from today’s $181.15.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Maintain and grow Life Sciences and Diagnostics Markets Group
Investment in growth aligns with Life Sciences market expansion.
Advances: Maintain and grow Life Sciences and Diagnostics Markets Group
Supports growth in Life Sciences and Diagnostics markets.
Advances: Expand non-GAAP EPS for fiscal year 2026
Improved margins support EPS growth objective.
Advances: Drive revenue growth for fiscal year 2026
Q2 results indicate strong revenue growth momentum.
Advances: Drive revenue growth for fiscal year 2026
Strong core growth supports revenue growth objective.
Advances: Drive revenue growth for fiscal year 2026
Positive revenue and EPS forecast supports growth objectives.
FDA approval enhances growth prospects and aligns with revenue objectives.